SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

September 19, 2013 09:00 ET

Nuvilex, Inc. Names Two Significant Partners on Its Way to Phase 3 Clinical Trials

NEW YORK, NY--(Marketwired - Sep 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made another subtle but significant move this week that seems to signal the company is in "go-mode" on its future Phase III pancreatic cancer clinical trials. When Nuvilex announced it had contracted with Inno Biologics to generate cell clones that will serve as the basis of the company's future Phase III cancer clinical trials, it was the second contract in as many weeks.

This could be a clarion call that the logistics stage leading up to Phase III clinical trials is clearly underway. Nuvilex's COO, Dr. Gerry Crabtree, said of the announcements, "The contracts with Fisher BioServices and Inno Biologics are both important steps on the road towards our future Phase III clinical trials in advanced, inoperable pancreatic cancer."

While the Fisher BioServices announcement seemed to get the ball rolling, it was this week's news that suggests Nuvilex may be closer than many realize. Dr. Crabtree said, "The Inno Biologics contract is the first actual step in the process of acquiring that number of drug-activating cells for encapsulation and these encapsulated cells will be used, together with ifosfamide, to treat patients with this devastating and deadly disease."

Nuvilex previously announced it had contracted Fisher BioServices for the long-term storage of cells required for its Phase III clinical trials. Dr. Crabtree says this contract ensures the safety and availability of cells to be used in those trials, "The Fisher BioServices arrangement gives Nuvilex a safety net, because its facilities will be used for long-term cell storage of the critically important ifosfamide-activating cells that are essential for Nuvilex's pancreatic cancer treatment. Should circumstances occur where the cells are 'lost' at any point in the overall process of obtaining the requisite number of cells necessary for the clinical trials, the Company will be able to recover the cell line from Fisher BioServices and resolve the 'problem'."

Both contracts seem to be flying under the radar, but make no mistake about it, with the logistics stage underway, the announcements should soon get more significant.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information:

Contact Information